References
- LeskeMCHeijlAHusseinMBengtssonBHymanLKomaroffEEarly Manifest Glaucoma Trial GroupFactors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma TrialArch Ophthalmol20031211485612523884
- The AGIS InvestigatorsThe Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deteriorationAm J Ophthalmol2000130442944011024415
- GordonMOBeiserJABrandtJDThe Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucomaArch Ophthalmol20021206714720 discussion 829–83012049575
- MigliorSTorriVZeyenTPfeifferNVazJCAdamsonsIthe EGPS GroupIntercurrent factors associated with the development of open-angle glaucoma in the European Glaucoma Prevention StudyAm J Ophthalmol2007144226627517543874
- KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 discussion 829–83012049574
- European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavona, ItalyDogma2008
- ManniGDenisPChewPThe safety and efficacy of brinzolamide 1%/timolol/0.5% fixed combination versus dorzolamide 2%/timolol/0.5% in patients with open-angle glaucoma or ocular hypertensionJ Glaucoma200918429330019365194
- AptelFDenisPBalancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucomaCurr Med Res Opin201127101949195821878000
- FechtnerRDRealiniTFixed combinations of topical glaucoma medicationsCurr Opin Ophthalmol200415213213515021225
- KhouriASRealiniTFechtnerRDUse of fixed-dose combination drugs for the treatment of glaucomaDrugs Aging200724121007101618020533
- TsaiJCMcClureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma200312539339814520147
- MundorfTKRauchmanSHWilliamsRDNotivolRthe Brinzolamide/Timolol Preference Study GroupA patient preference comparison of Azarga (brinzolamide/timolol fixed combination) vs Cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertensionClin Ophthalmol20082362362819668763
- VoldSDEvansRMStewartRHWaltersTMallickSA one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertensionJ Ocul Pharmacol Ther200824660160519049301
- RossiGCPasinettiGMSandoloFBordinMBianchiPEFrom dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch studyExpert Opin Pharmacother201112162425243121679090
- LanzlIRaberTEfficacy and tolerability of the fixed combination of brinzolamide 1% and timolol 0.5% in daily practiceClin Ophthalmol2011529129821468336
- AZARGA® Eye Drops Suspension [summary of product characteristics]Hünenberg, SwitzerlandAlcon Laboratories, Inc2008 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000960/WC500029827.pdfAccessed. April 30, 2012
- COSOPT® Sterile Ophthalmic Solution [package insert]Whitehouse Station, NJMerck and Co, Inc2011
- SyedMFLoucksEKUpdate and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertensionClin Ophthalmol201151291129621966204
- BarnebeyHKwokSYPatients’ acceptance of a switch from dorzolamide to brinzolamide for the treatment of glaucoma in a clinical practice settingClin Ther200022101204121211110231
- RossiGCPasinettiGMScudellerLRadaelliRBianchiPEDo adherence rates and glaucomatous visual field progression correlate?Eur J Ophthalmol201121441041421140373
- DohertyMFraserSPhelanPBrinzolamide-timolol suspension: acceptability and side effect profileClin Ophthalmol2011541942321499567